Emmanuel Bujold - Gynecology

Author Information

Emmanuel Bujold is affiliated with the Department of Obstetrics and Gynecology at the Faculty of Medicine, Université Laval, located in Quebec, Canada. He has made significant contributions to the field through his extensive research, particularly focusing on preeclampsia and fetal growth restriction.

Research Contributions

Emmanuel Bujold's research primarily revolves around the prediction and early detection of preeclampsia and fetal growth restriction. His recent works have explored various biomarkers and methods for early diagnosis, such as placental soluble fms-like tyrosine kinase 1 (sFlt-1), Pregnancy-associated plasma protein-A, and Placental growth factor. Additionally, he has investigated the use of low-dose aspirin in twin pregnancies and the potential impacts of in utero exposure to medications like metformin on offspring. His work includes both experimental studies and systematic reviews, significantly contributing to clinical practices and guidelines in obstetrics and gynecology.

Aliases

E Bujold, E. Bujold, Emmanuel Bujold

Publication and Citation Metrics

Metric	Value
Total Papers	405
Total Citations	13,550
H-index	61

Publications:

First-trimester placental soluble fms-like tyrosine kinase 1 (sFlt-1) for the prediction of preeclampsia

DOI: 10.1016/j.ajog.2021.11.584

Year: 2022

Optimal Screening for Preeclampsia in the First Trimester of Pregnancy.

DOI: 10.1161/HYPERTENSIONAHA.121.18421

Year: 2022

First-trimester prediction of preeclampsia: A comparison between Pregnancy-associated plasma protein-A and Placental growth factor

DOI: 10.1016/j.ajog.2021.11.755

Year: 2022

Reply to "Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase-1 in Preeclampsia: A novel cut-off point?"

DOI: 10.1016/j.jogc.2020.11.015

Year: 2021

Aspirin Responsiveness at a Dose of 80 mg and Its Impact on Birth Weight when Used in Twin Pregnancies: The GAP Pilot Randomized Trial.

DOI: 10.1055/s-0041-1727215

Year: 2021

VP42.07: First trimester prediction of preterm pre‐eclampsia using the Fetal Medicine Foundation algorithm

DOI: 10.1002/uog.24612

Year: 2021

Short-term outcomes of phosphodiesterase type 5 inhibitors for fetal growth restriction: a study protocol for a systematic review with individual participant data meta-analysis, aggregate meta-analysis, and trial sequential analysis

DOI: 10.1186/s13643-021-01849-5

Year: 2021

Proteomic Analysis of Maternal Urine for the Early Detection of Preeclampsia and Fetal Growth Restriction

DOI: 10.3390/jcm10204679

Year: 2021

The Association between Maternal Placental Growth Factor and Placental Maternal Vascular Malperfusion Lesions.

DOI: 10.1016/j.jogoh.2021.102179

Year: 2021

Commentary: In Utero Exposure to Metformin Reduces the Fertility of Male Offspring in Adulthood

DOI: 10.3389/fendo.2021.815532

Year: 2021

When is Labor Augmentation Necessary?

What types of STI screenings are available?

How to Choose the Right Reminder System?

What Are the Advantages of MRI Over Other Imaging Techniques?

What is Cord Blood Banking?

What Should Patients Do to Navigate Insurance Variability?

How Often Should Women Stretch?

How Can Women Manage Stress?

How Does Epilepsy Impact Menstrual Cycles?

Is Excessive Sweating Hereditary?

Partnered Content Networks

Relevant Topics